Trimetazidine Improves Mitochondrial Dysfunction in SOD1G93A Cellular Models of Amyotrophic Lateral Sclerosis through Autophagy Activation
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25063251 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Illari Salvatori und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of Roma "La Sapienza", 00185 Rome, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Trimetazidine, Mitochondrial Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council, Ministero della Salute, Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica.
Abstract (Originalsprache)
Amyotrophic Lateral Sclerosis (ALS) is considered the prototype of motor neuron disease, characterized by motor neuron loss and muscle waste. A well-established pathogenic hallmark of ALS is mitochondrial failure, leading to bioenergetic deficits. So far, pharmacological interventions for the disease have proven ineffective. Trimetazidine (TMZ) is described as a metabolic modulator acting on different cellular pathways. Its efficacy in enhancing muscular and cardiovascular performance has been widely described, although its molecular target remains elusive. We addressed the molecular mechanisms underlying TMZ action on neuronal experimental paradigms. To this aim, we treated murine SOD1G93A-model-derived primary cultures of cortical and spinal enriched motor neurons, as well as a murine motor-neuron-like cell line overexpressing SOD1G93A, with TMZ. We first characterized the bioenergetic profile of the cell cultures, demonstrating significant mitochondrial dysfunction that is reversed by acute TMZ treatments. We then investigated the effect of TMZ in promoting autophagy processes and its impact on mitochondrial morphology. Finally, we demonstrated the effectiveness of TMZ in terms of the mitochondrial functionality of ALS-rpatient-derived peripheral blood mononuclear cells (PBMCs). In summary, our results emphasize the concept that targeting mitochondrial dysfunction may represent an effective therapeutic strategy for ALS. The findings demonstrate that TMZ enhances mitochondrial performance in motor neuron cells by activating autophagy processes, particularly mitophagy. Although further investigations are needed to elucidate the precise molecular pathways involved, these results hold critical implications for the development of more effective and specific derivatives of TMZ for ALS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, University of Roma "La Sapienza", 00185 Rome, Italy.
- IRCCS, Fondazione Santa Lucia, 00179 Rome, Italy.
- Department of Systems Medicine, Tor Vergata University of Rome, 00133 Rome, Italy.
- Department of Biology, Tor Vergata University of Rome, 00133 Rome, Italy.
- Department of Science, LIME, University of Roma Tre, 00165 Rome, Italy.
- Unit of Neurology, Fondazione PTV Policlinico Tor Vergata, 00133 Rome, Italy.
ORCID-Profile: Veronica Marabitti, Marco Rosina, Gianmarco Fenili, Mariangela Goglia, Sandra Moreno, Nicola Biagio Mercuri, Francesca Nazio, Patrizia Longone, Alberto Ferri, Cristiana Valle
Förderung
- National Research Council
- Ministero della Salute
- Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica
- Italian Association for Cancer Research
- Regione Lazio
- Ministero dell'Università e Ricerca Italy
- CNR
- Italian Ministry of Health
Zitieren
APA
Salvatori, I., Nesci, V., Spalloni, A., Marabitti, V., Muzzi, M., Zenuni, H., Scaricamazza, S., Rosina, M., Fenili, G., Goglia, M., Boffa, L., Massa, R., Moreno, S., Mercuri, N. B., Nazio, F., Longone, P., Ferri, A., & Valle, C. (2024). Trimetazidine Improves Mitochondrial Dysfunction in SOD1G93A Cellular Models of Amyotrophic Lateral Sclerosis through Autophagy Activation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063251
Vancouver
Salvatori I, Nesci V, Spalloni A, Marabitti V, Muzzi M, Zenuni H, et al. Trimetazidine Improves Mitochondrial Dysfunction in SOD1G93A Cellular Models of Amyotrophic Lateral Sclerosis through Autophagy Activation. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063251
BibTeX
@article{Salvatori2024,
author = {Salvatori, Illari and Nesci, Valentina and Spalloni, Alida and Marabitti, Veronica and Muzzi, Maurizio and Zenuni, Henri and Scaricamazza, Silvia and Rosina, Marco and Fenili, Gianmarco and Goglia, Mariangela and Boffa, Laura and Massa, Roberto and Moreno, Sandra and Mercuri, Nicola Biagio and Nazio, Francesca and Longone, Patrizia and Ferri, Alberto and Valle, Cristiana},
title = {Trimetazidine Improves Mitochondrial Dysfunction in SOD1G93A Cellular Models of Amyotrophic Lateral Sclerosis through Autophagy Activation},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25063251}
}
EUVIMED